Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis

Table 1 Characteristics of included trials

Trial	Interventions	Dose (mg/day)	Comparator	No of patients	Course (weeks)	Follow-up (weeks)	Source
DiaconAH 2009,2012	Bedaquiline	1600,1200	placebo	47	8	104	journal article [22,23]
Trail NCT00449644	Bedaquiline	1600,1200	placebo	160	24	104	clinical trial website [24], study register
Gler MT 2012	Delamanid	400,200	placebo	481	8	104	journal article [25], clinical trial website [26]
Trial NCT00685360	Delamanid	400,200	placebo	192	8	104	journal article [27],
Zhang Q 2013	Delamanid	400,200	placebo	38	24	104	journal article [28]
Carroll MW 2013	Metronidazole	1500	placebo	35	8	24	journal article [29]
Trail NCT00425113	Metronidazole	1500	placebo	35	8	72	clinical trial website [30]
Trail NCT00082173	Moxifloxacin	400	placebo	146	8	0	clinical trial website [31]
Chen Y 2013	Moxifloxacin	400	placebo	74	52	0	journal article [32]
Koh WJ 2013	Moxifloxacin	400	levofloxacin	90	12	0	journal article [33], clinical trial website [34]
Liang LL 2011	Moxifloxacin	400	levofloxacin	46	72	0	journal article [35]
Koh WJ 2013	Levofloxacin	750	moxifloxacin	92	12	0	journal article [33], clinical trial website [34]
Liang LL 2011	Levofloxacin	600	moxifloxacin	36	72	0	journal article [35]

BR: background drug regimen treatment, INH: isoniazid, PZA: pyrazinamide, MOX: moxifloxacin, EMB: ethambutol, RIF: rifampicin, OFL: ofloxacin, AMK: amikacin.